Alnylam Swallows Poison Pill, Unveils New Systemic Delivery Data, Inks Licensing Deals | GenomeWeb

Alnylam Pharmaceuticals has adopted a shareholder rights plan designed to stave off a potential hostile takeover, presented new data on its systemic RNAi efforts, and signed two intellectual property out-licensing deals.

The disclosures cap a busy couple of weeks for the Cambridge, Mass.-based RNAi drugs shop despite an otherwise characteristically slow summer month. The following is a wrap-up of Alnylam's developments.

Poison Pill

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.